Telomerase and its potential for therapeutic intervention
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Telomerase and telomeres are attractive targets for anticancer therapy. This is supported by the fact that the majority of human cancers express the enzyme telomerase which is essential to maintain their telomere length and thus, to ensure indefinite cell proliferation – a hallmark of cancer. Tumours have relatively shorter telomeres compared to normal cell types, opening the possibility that human cancers may be considerably more susceptible to killing by agents that inhibit telomere replication than normal cells. Advances in the understanding of the regulation of telomerase activity and the telomere structure, as well as the identification of telomerase and telomere associated binding proteins have opened new avenues for therapeutic intervention. Here, we review telomere and telomerase biology and the various approaches which have been developed to inhibit the telomere/telomerase complex over the past decade. They include inhibitors of the enzyme catalytic subunit and RNA component, agents that target telomeres, telomerase vaccines and drugs targeting binding proteins. The emerging role of telomerase in cancer stem cells and the implications for cancer therapy are also discussed. British Journal of Pharmacology (2007) 152, 1003–1011; doi:10.1038/sj.bjp.0707374; published online 2 July 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of telomeres
Blackburn, E. H. (1991) · Nature · doi:10.1038/350569a0 · Cited by 3,596
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917 · cited 1×
“The earliest measurable event following telomere-associated DNA-damage signalling is the phosphory- British Journal of Pharmacology (2007) 152 1003–1011 lation of H2AX (g-H2AX) (Figure 2) (d’Adda di Fagagna et al., 2003).”
BackgroundA survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 2×
“By contrast, normal tissues adjacent to tumour and human somatic tissues, other than stem cells, do not possess detectable levels of telomerase (Kim et al., 1994; Shay and Bacchetti, 1997).”
BackgroundCreation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Telomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science · doi:10.1126/science.277.5328.955 · Cited by 2,256
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 4×
“The telomere/telomerase complex In vitro, hTERC and hTERT are sufficient to bestow telomerase activity (Feng et al., 1995; Nakamura et al., 1997).”
BackgroundInfluentialTelomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomere elongation in immortal human cells without detectable telomerase activity
Bryan, T. M., Englezou, A., Gupta, J., Bacchetti, S., & Reddel, R. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00098.x · Cited by 1,279 · cited 4×
“Although telomerase is the major mediator of telomere elongation, small fractions of yeast and mammalian cells that lack telomerase can operate a recombination-dependent mechanism, termed alternative lengthening of telomeres (ALT) (Bryan et al., 1995; Lundblad and Blackburn, 1993).”
BackgroundInfluentialControl of telomere length by the human telomeric protein TRF1
van Steensel, B., & de Lange, T. (1997) · Nature · doi:10.1038/385740a0 · Cited by 1,219
p53- and ATM-Dependent Apoptosis Induced by Telomeres Lacking TRF2
Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., & de Lange, T. (1999) · Science · doi:10.1126/science.283.5406.1321 · Cited by 1,086
Protection of mammalian telomeres
de Lange, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205080 · Cited by 942 · cited 2×
“Two structures of the 30-single stranded (TTAGGG)n overhang have been proposed: one suggesting the presence of a T-loop, which would result from a foldback of the 30overhang into a loop of duplex DNA, the other proposes the formation of dimers and tetramers involving G-quadruplexes (de Lange, 2002).”
BackgroundAn alternative pathway for yeast telomere maintenance rescues est1− senescence
Lundblad, V., & Blackburn, E. H. (1993) · Cell · doi:10.1016/0092-8674(93)90234-h · Cited by 942 · cited 4×
“Although telomerase is the major mediator of telomere elongation, small fractions of yeast and mammalian cells that lack telomerase can operate a recombination-dependent mechanism, termed alternative lengthening of telomeres (ALT) (Bryan et al., 1995; Lundblad and Blackburn, 1993).”
BackgroundInfluentialHerbert, B.-S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., & Corey, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14276 · Cited by 539 · cited 2×
“Cells treated with this oligomer took more than 100 days to eventually die, but inhibited telomerase activity at very low concentrations (Figure 1; see principle of telomerase inhibition) (Herbert et al., 1999).”
BackgroundConditional telomerase induction causes proliferation of hair follicle stem cells
Sarin, K. Y., Cheung, P., Gilison, D., Lee, E., Tennen, R. I., Wang, E., Artandi, M. K., Oro, A. E., & Artandi, S. E. (2005) · Nature · doi:10.1038/nature03836 · Cited by 425
A highly selective telomerase inhibitor limiting human cancer cell proliferation
Damm, K., Hemmann, U., Garin‐Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6958 · Cited by 422
Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis
González-Suárez, E., Samper, E., Flores, J. M., & Blasco, M. A. (2000) · Nature Genetics · doi:10.1038/79089 · Cited by 347 · cited 2×
“Particularly useful to validate telomerase as a cancer inhibitory target were studies with hTERC knockout mice and ectopic expression of dominant-negative hTERT in human tumour cells (Blasco et al., 1997; Hahn et al., 1999b; Gonzalez-Suarez et al., 2000).”
BackgroundStrahl, C., & Blackburn, E. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.1.53 · Cited by 335 · cited 1×
“However, high drug concentrations are required (4100 mM) for enzyme inhibition and its antiproliferate activity is weak (Strahl and Blackburn, 1996; Brown et al., 2003).”
BackgroundShort Telomeres, even in the Presence of Telomerase, Limit Tissue Renewal Capacity
Hao, L.-Y., Armanios, M., Strong, M. A., Karim, B., Feldser, D. M., Huso, D., & Greider, C. W. (2005) · Cell · doi:10.1016/j.cell.2005.11.020 · Cited by 302 · cited 1×
“Overexpression of the catalytic subunit of telomerase, hTERT, has been found to promote stem cell mobilization, whereas short telomeres have been reported to cause stem cell failure (Hao et al., 2005; Sarin et al., 2005).”
BackgroundIn vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1215 · Cited by 271 · cited 3×
“GRN163L (Geron Corp., CA, USA) is the first anti-telomerase agent to enter the clinic (Dikmen et al., 2005; Gellert et al., 2006; Jackson et al., 2007).”
BackgroundTelomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect
Salvati, E., Leonetti, C., Rizzo, A., Scarsella, M., Mottolese, M., Galati, R., Sperduti, I., Stevens, M. F. G., D’Incalci, M., Blasco, M., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32461 · Cited by 266 · cited 2×
“This might in part explain their single agent activity and rapid onset of activity against in vivo human tumour models with relatively short telomeres (Burger et al., 2005; Phatak et al., 2007; Salvati et al., 2007).”
BackgroundAntiadhesive Effects of GRN163L—An Oligonucleotide N3′→P5′ Thio-Phosphoramidate Targeting Telomerase
Jackson, S. R., Zhu, C.-H., Paulson, V., Watkins, L., Dikmen, Z. G., Gryaznov, S. M., Wright, W. E., & Shay, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2306 · Cited by 72 · cited 1×
“GRN163L (Geron Corp., CA, USA) is the first anti-telomerase agent to enter the clinic (Dikmen et al., 2005; Gellert et al., 2006; Jackson et al., 2007).”
Background
Cited by
The hallmarks of cancer: A long non-coding RNA point of view
Gutschner, T., & Diederichs, S. (2012) · RNA Biology · doi:10.4161/rna.20481 · Cited by 1,802
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728
Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs?
Selman, M., Pardo, A., & Kaminski, N. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050062 · Cited by 336
Novel anticancer therapeutics targeting telomerase
Ruden, M., & Puri, N. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.007 · Cited by 310
Metadata
- Authors
- Phatak, P., & Burger, A. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-12
- Volume
- 152
- Issue
- 7
- Pages
- 1003-1011
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2119993986
- Cited by
- 90
- References
- 22
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.